Concepedia

Milo Frattini

MF

77

Publications

11.2K

Citations

41

H-Index

1999

Active since

Affiliations

Istituto Cantonale di Patologia(Current)

Fondazione IRCCS Istituto Nazionale dei Tumori

IFOM

Ospedale San Giovanni Bellinzona

Candiolo Cancer Institute

Milo Frattini is an author at Istituto Cantonale di Patologia specializing in medicine, pathology, and cancer research.

ORCID

Top concepts

Publications per year

1999–2022

77

Publications

77

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

, , +5

Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Federica Di Nicolantonio, Miriam Martini, Francesca Molinari et al. · Journal of Clinical Oncology · 2008 · 1.6K citations · Full text

, , +13

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio et al. · JAMA · 2010 · 743 citations

<i>PIK3CA</i> Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

Andrea Sartore‐Bianchi, Miriam Martini, Francesca Molinari et al. · Cancer Research · 2009 · 735 citations

, , +17

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

Milo Frattini, Piercarlo Saletti, Elena Romagnani et al. · British Journal of Cancer · 2007 · 536 citations · Full text

Rows per page

1–5 of 77